Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly ( DrugBank: Batoclimab )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
14慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー1

14. 慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー


臨床試験数 : 175 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05581199
(ClinicalTrials.gov)
December 15, 202212/10/2022To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPA Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Inflammatory Demyelinating PolyneuropathyDrug: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly;Drug: Batoclimab 340 mg SC weekly;Drug: PlaceboImmunovant Sciences GmbHNULLRecruiting18 YearsN/AAll240Phase 2United States